The PennZone

~ Q'Apel Medical (Q'Apel), a leading medical device company, has recently announced the receipt of CE mark certification for its innovative Armadillo SelectFlex™ Neurovascular Access System. This groundbreaking 7F system, equipped with patented SelectFlex™ Technology, is specifically designed to simplify neurovascular interventions.

According to Pascal Jabbour, MD, FAANS, FACS, FAHA, The Angela and Richard T. Clark Distinguished Professor of Neurological Surgery and Radiology at Thomas Jefferson University Hospital in Philadelphia, PA, navigating the complex anatomy of the neurovasculature can be extremely challenging. While flexible access catheters are necessary for maneuvering through tight twists and turns, they often lack the necessary support and stability for device delivery once in position. However, with Armadillo's one-and-done solution, physicians can easily transform the catheter from highly trackable to highly supportive as needed throughout the procedure with just a simple injection or withdrawal of 0.2cc of saline.

More on The PennZone

• 6 Holiday Looks That Scream "Old Money" But Cost Less Than Your Christmas Tree
• Tickeron Launches Next-Gen AI Corridor Bots: Consistent Exits for Stocks and ETFs
• From Cheer to Courtroom: The Hidden Legal Risks in Your Holiday Eggnog
• Controversial Vegan Turns Rapper Launches First Song, "Psychopathic Tendencies."
• Inside the Fight for Affordable Housing: Avery Headley Joins Terran Lamp for a Candid Bronx Leadership Conversation

The Armadillo Neurovascular Access System with SelectFlex™ Technology offers physicians the versatility they need to confidently tackle a wide range of neurovascular interventions. Its low-profile 7F catheter allows for a biaxial approach regardless of access site, accelerating delicate procedures and eliminating the complexity and cost associated with conventional tri-axial configurations.

Jodie Fam, CEO of Q'Apel Medical, believes that their new system addresses the limitations of current neurovascular access catheters. She states that it provides a unique option for hospitals to standardize device usage while reducing inventory constraints and cost per procedure. Fam also expresses her gratitude towards their team for achieving this critical milestone and looks forward to expanding their international portfolio by delivering this meaningful solution to the European market and beyond in the coming months.

With its revolutionary technology and potential cost-saving benefits for hospitals, Q'Apel's Armadillo SelectFlex™ Neurovascular Access System is set to revolutionize neurovascular interventions and improve patient outcomes. The company's success in the U.S. market has paved the way for its expansion into the international market, bringing this innovative solution to more physicians and patients in need.

---

Show All News | Report Violation